- The center features a 1,500-square-meter lab and 700 square meters of office space.
- WACKER invested a double-digit million-euro sum in the facility.
- Research focuses on biopharmaceuticals and food ingredients, including mRNA-based therapies.
- The center aims to reduce time from research to market.
Facility Overview
The WACKER Biotechnology Center in Munich spans 1,500 square meters for laboratory and technical competence, alongside 700 square meters of office space. It is designed to enhance research capabilities in biopharmaceuticals and food ingredients.
Investment and Purpose
WACKER Chemie AG has invested a double-digit million-euro sum in this facility. The center aims to consolidate biotechnological R&D, improving efficiency and reducing the time from lab research to market implementation.
Research Focus
The center's research will concentrate on manufacturing processes for biopharmaceuticals, including proteins and nucleic acids, crucial for developing innovative therapies like mRNA-based treatments. Additionally, it will focus on creating ingredients for food and dietary supplements to promote sustainable nutrition.
Strategic Importance
Located in Munich's Sendling quarter, the center integrates with WACKER's existing research site, which has been active in biotechnology since the 1980s. This expansion addresses the previous limitations in research capacity, providing space for around 90 employees with state-of-the-art equipment.
